Skip to main content

Dermagnostix receives EIC funding of 2,5 million euros

Transfer, Awards & Grants,

The medical technology company Dermagnostix GmbH is a joint spin-off of Helmholtz Munich, the Technical University (TU) Munich and Hahn-Schickard. Its goal: to redefine molecular diagnostics in dermatology. Dermagnostix has now qualified as one of 30 companies for a direct grant from the European Innovation Council (EIC) and will receive 2.5 million euros.

The medical technology company Dermagnostix has one mission: to develop modern diagnostic methods and enable personalized therapies for patients with skin diseases. In fact, skin diseases such as psoriasis and atopic dermatitis are among the most common inflammatory diseases. However, many of the patients are misdiagnosed, as the disease types sometimes overlap considerably. Dermagnostix sought a solution to this problem: the starting point was a molecular test jointly developed and patented at Helmholtz Munich and the Technical University of Munich to distinguish between psoriasis and eczema, which are difficult to differentiate using conventional methods. The company finally brought the molecular test to market with PsorX – a fully automated portable laboratory that quickly and reliably enables differential diagnosis of psoriasis and eczema.

Dermagnostix convinced the jury of the EIC out of about 1000 applications from Europe and can be pleased about its largest public grant so far. The so-called EIC Accelerator is a European innovation program that supports small and medium-sized companies, especially start-ups and spinout companies, in the further development and dissemination of promising technologies. Twice a year, about 70 companies are selected for funding. With the grant money, the young company now has the opportunity to further develop their product portfolio and bring it to market. Among other things, the “Analyzer” analysis device and the “PsorX-LabDisk” are to be further developed and the commercialization strategy worked out.